Home > Advanced Cell Technology Salary

Advanced Cell Technology Salary

  • 91
  • 58
  • 28
Advanced Cell Technology average salary is $48,000, median salary is $48,000 with a salary range from $48,000 to $48,000.
Advanced Cell Technology salaries are collected from government agencies and companies. Each salary is associated with a real job position. Advanced Cell Technology salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 1 Advanced Cell Technology Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Chiropractor 48,000-48,000 Milpitas, CA, 95035 2014 Advanced Cell Technology Chiropractor Salaries (1)
Advanced Cell Technology Milpitas, CA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Advanced Cell Technology salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Advanced Cell Technology Jobs
Inside Sales Representative
Advanced Cell Diagnostics, Inc. - Newark, CA
Supervisor Reagent Manufacturing
Advanced Cell Diagnostics, Inc. - Newark, CA
Yale New Haven Hospital - New Haven, CT
1st Shift Advanced Coating Cell Leader
United Technologies Corporation - East Hartford, CT
See more Advanced Cell Technology Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Advanced Cell Technolo... Information
  • Advanced Cell Technology, Inc.
  • Industry: Biotech/Healthcare
  • City: Santa Monica, CA
  • Advanced Cell Technology was formed in 1994 as a subsidiary of a poultry genetics company. ACT has since that time been dramatically transformed from its initial agricultural focus to a world leader in autologous regenerative medicine. While the company is still, to a limited extent, engaged in animal cloning for technology development and pre-clinical trial purposes, the company¡¯s efforts are now on human cell therapy. The company has chosen to out-license all non-core application areas and has divested itself of its agricultural cloning subsidiary. The company remains privately held.